DBV Technologies reported $526.5M in Market Capitalization this August of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.53B 199M Aug/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amarin USD 290M 51M Dec/2025
BioCryst Pharmaceuticals USD 1.9B 643M Aug/2026
BioMarin Pharmaceutical USD 11.71B 651M Aug/2026
DBV Technologies USD 1.23B 327M Mar/2026
Halozyme Therapeutics USD 10.91B 1.63B Aug/2026
Incyte USD 26.84B 4.19B Aug/2026
Insmed USD 19.68B 3.43B Aug/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Sarepta Therapeutics USD 1.5B 402M Aug/2026
Ultragenyx Pharmaceutical USD 2.12B 1.16B Aug/2026
United Therapeutics USD 24.42B 1.42B Aug/2026